ABSTRACT
Chromatin remodeling and protein acetylation control gene expression and consequently regulate cellular growth and differentiation. Here we review the role of individual chromatin remodeling factors, acetyltransferases and deacetylases in the establishment and maintenance of different cell lineages and in the genesis of some human diseases.
INTRODUCTION
The clarification of the mechanisms leading to the establishment of highly specialized cell lineages starting from a fertilized egg remains elusive and it continues to be a fascinating area of investigation.
Asymmetric partitioning of maternal material to daughter cells and extracellular signals mediated by either soluble or membrane-anchored molecules contribute to instruct a group of given cells to adopt a defined fate.
Recent findings indicate that while the fate may be defined is not definitive. Some cells reserve the option of changing their mind and, under circumstances that remain to be investigated, can and will modify their phenotype (65, 89, 110, 212, 127, 71) .
Mechanistically, generating most-if not all-cell types relies on a common feature. That is, no matter what the nature of the signals and the pathways chosen to transduce them may be, the resulting information needs to reach the nucleus of the cell to influence gene expression. Of the many genes comprising the genome of a multicellular organism, only a defined combination is turned on in a given subset of cells. Therefore, cell differentiation is largely a matter of transcriptional regulation.
The DNA regions regulating gene expression are not readily accessible to transcription factors because of a physical barrier represented by the chromatin (104, 75, 83, 283 ). An increased DNA accessibility to a variety of enzymes and chemical probes denotes a redistribution of the nucleosomal array (279) -a phenomenon known as chromatin remodeling -that precedes transcriptional activation. This process is brought about by ATPdependent molecular machines comprised of several protein subunits (130, 68, 70) . Chromatin remodeling facilitates the binding of transcription factors to nucleosome particles, at least in an in vitro system (51).
Whilst DNA binding of transcription factors and chromatin remodeling enzymes is a prerequisite for gene activation, it is not sufficient to initiate transcription. As elegantly illustrated in yeast, a chronologically ordered series of events is required to activate transcription (50). The yeast transcriptional activator Swi5 recruits the chromatin remodeling SWI/SNF complex on the promoter of the HO gene. The engagement of SWI/SNF is not sufficient to stimulate HO transcription, which is allowed to proceed only after the acetyltransferase Gcn5 joins the Swi5-SWI/SNF complex and promotes acetylation of the histones surrounding the HO gene. Surprisingly, once SWI/SNF and Gcn5 have been recruited to the HO promoter, the presence of the activator Swi5 becomes dispensable. Recent experiments indicate that retention of the SWI/SNF complex on promoter regions is accomplished by histone acetylation and that once acetylation has been achieved, the transcriptional activator is no longer needed (96) . Therefore, acetylation of histonesand possibly of other proteins-seems to temporally follow chromatin remodeling. At the same time, histone acetylation is necessary to productively retain remodeling machines on chromatin in a complex series of events culminating in transcription (96) . An increasing number of proteins previously known to be transcriptional regulators including p300/CBP (199) (12), P/CAF (287), GCN5 (33), ACTR (43), Src-1 (249) and TAFII250 (167) have been shown to have intrinsic histone acetyltransferase (HAT) activity (for recent reviews on HAT enzymes see (32, 18, 30, 128, 48) . A link between histone acetylation, methylation and eukaryotic gene expression has been suggested since 1964 (1) . Further studies have indicated that active euchromatin is associated with hyperacetylated histones (25,63) whereas the histones of inactive heterochromatin are hypoacetylated (29, 114 ). An additional evidence supporting the role of histone acetylation and deacetylation in regulating transcription has emerged from the isolation and characterization of several mammalian histone deacetylases with the founding member HD1 (260) being related to the yeast transcriptional repressor Rpd3 (181, 266) . How histone acetylation promotes transcription is not well understood. It is generally believed that acetylation at the ε-amino groups neutralizes the positive charge of specific lysines located at the N-terminus of histones H3 and H4 therefore weakening the electrostatic interaction of histones with DNA. The resulting loosening of the nucleosome structure would favor binding of transcription factors to their DNA targets (32). On the contrary, removal of acetyl groups from the ε−amino groups of lysines could reinforce the electrostatic interaction between histones and DNA precluding transcriptional activation. While this scenario may be partially correct, the recent solution of the crystal structure of the nucleosome core particles indicates that the histone N-terminus (the tail) does not seem to contact directly the DNA but rather seems to interact with adjacent nucleosomes (145) . It is therefore likely that acetylation modifies several proteins engaged in controlling transcription including histones, enhancer-binding factors and members of the basal transcriptional machinery (105) and that stimulation of transcription derives from the sum of these modifications (48).
Here we will review recent advancements in the field of transcriptional regulation of different cell-types with a particular focus on the role of acetylation/deacetylation.
SKELETAL MYOGENESIS
The understanding of how skeletal muscle cells are specified, maintained and undergo differentiation has received a tremendous impetus since the isolation of MyoD (53). MyoD-related factors have been isolated that belong to the same family of transcriptional activators, the myogenic bHLH proteins (277, 202) . The myogenic bHLH interact with a specific DNA motif, the E-box, and they are assisted in promoting transcription by two general activators, the E proteins and the MADS-box -containing factors MEF2 (134, 170) . Overexpression of any of the myogenic bHLH proteins redirects the fate of both established cell lines and primary cells to take up the skeletal muscle phenotype (280) . Genetic ablation of the individual genes in animal models has revealed a specific role for each of the myogenic bHLH. MyoD and Myf-5 are responsible for the specification (28, 231, 232) whereas myogenin controls differentiation of skeletal muscle cells (97, 177) . MyoD is also involved in muscle regeneration (159). The role of MRF4 is less clear at the moment (201) .
Chromatin remodeling
Over the years, it has been appreciated that chromatin remodeling is a hallmark of the initial steps that may result in gene activation and that chromatin remodeling enzymes are involved in regulating both chromatin modification and gene expression (267) . MyoD expression causes chromatin remodeling of muscle-specific genes including those for myogenin, muscle creatine kinase and MyoD itself (73). Importantly, changes in chromatin structure could be directly ascribed to the activity of MyoD since they were observed in the presence of the protein synthesis inhibitor cycloheximide (73). The effects exerted by MyoD on chromatin are highly specific and are limited to regulatory regions controlling expression of musclerestricted genes. In fact, the structure of the chromatin surrounding the locus control region of the beta globin cluster and the immunoglobulin enhancer -active in red blood cells and lymphocytes, respectively-is not affected by MyoD expression (73). Two regions of MyoD, the cysteine-histidine rich domain (73) and the carboxylterminus (73,19), mediate chromatin remodeling activity. Reflecting the different roles of the individual myogenic bHLH proteins observed in the animal, Myf-5 but not myogenin also causes chromatin modification at muscle-specific loci (73). The SWI/SNF complex or related chromatin remodeling complexes (70) may mediate the activity of MyoD. Upon inducible expression of a dominant-negative version of either BRG1 or BRM, the ATPase subunits of SWI/SNF, MyoD-dependent conversion of NIH3T3 fibroblasts is prevented and, most importantly, this correlates with lack of chromatin remodeling on the promoter of an endogenous musclespecific gene (55) . Recent experiments suggest that SWI/SNF associates with MyoD (C. Palmer and M.A. Rudnicki, personal communication).
Co-activation and acetylation 3.2.1. MyoD
Numerous proteins counteract the ability of skeletal muscle cells to differentiate in tissue culture. Among these are the viral oncoproteins E1A and SV 40 T antigen (222) . The transcriptional coactivator p300 has been purified exploiting its ability to interact with E1A (94, 60). The SV40 T antigen also interacts with p300 (7, 61). While E1A interacts with several cellular proteins including pRb, p130 and p107 (94), deletion of 30 amino acids at its N-terminus prevents p300 binding and greatly diminishes the ability of E1A to prevent muscle differentiation (38) -despite the integrity of the other E1A modules necessary to interact with the aforementioned cellular proteins-. These findings prompted several groups to ask the question of whether p300 may be a coactivator of muscle transcription. Indeed, p300 was found to interact and augment transcription mediated by both MyoD (289, 62, 221, 233) and MEF2 (233) and microinjection of p300-specific antisera blocked differentiation of cultured muscle cells (223, 62 (233) reported that the N-terminal region of MyoDcontaining an acidic activator domain-was to mediate both interaction and sense coactivation of MyoD. The Nterminal region of MyoD is required for cooperative binding of MyoD to two adjacent DNA binding sites (Eboxes) and transcriptional activation of MCK enhancer (276) . Deletion of 53 amino acids located at the N-terminal region of MyoD renders it inactive when tested in transient transfection assays (278) whilst it does not seem to affect the ability of stably transfected MyoD to activate transcription of endogenous muscle genes (259) . It may be possible that, in the cellular context, MyoD may simultaneously interact with p300 through both the N-terminal and the bHLH regions. On p300, two regions encompassing amino acids 1-596 and including the cysteine/histidine-rich region 1 (C/H1) (60) and amino acids 1572-1900 spanning the C/H3 region (60) independently mediate interaction with MyoD and possibly other myogenic bHLH proteins (289, 62, 233, 228) . In addition, p300 seems to be also involved in controlling cell cycle exit of myoblasts induced to differentiate. Indeed, microinjection of anti-p300 antibodies prevents upregulation of the cell cycle inhibitor p21 and abrogates MyoD-dependent cell cycle arrest (62, 221). Thus, p300 provides a pivotal function in at least two critical steps of the myogenic program, that is cell cycle arrest and expression of muscle-specific genes. It is likely that E1A and SV40 T Ag may cause cell cycle progression and block expression of muscle-restricted proteins by competing with MyoD for p300 binding. The p300/CBP-associated factor P/CAF competes with the oncoprotein E1A for binding to p300/CBP (287) . Both P/CAF and MyoD interact with an overlapping but distinct region of p300 (223) . Furthermore, P/CAF directly interacts with MyoD albeit with a much lower affinity than that exhibited for p300 (223) .
Microinjection experiments conducted with a P/CAF antiserum resulted in a blockade of muscle differentiation indicating the need of P/CAF for this process (223) . It is worth noting that the P/CAF antisera utilized in those experiments cross-react with GCN5 (R. L. Schiltz, personal communication) raising the possibility that both P/CAF and GCN5 were neutralized. Based on coimmunoprecipitation experiments and relative protein affinities, a model has been proposed where the primary function of p300 would be to recruit P/CAF on MyoD to activate transcription. Both p300/CBP and P/CAF have intrinsic acetyltransferase activities (199, 12, 287) raising the question of why MyoD engages two different proteins with the same enzymatic activity to promote transcription. Using deletion mutants of both p300 and P/CAF with no detectable histone acetyltransferase activity, MyoDdependent transcription was found to require the HAT activity of P/CAF but not of p300 (224) . This difference is unlikely to reside in the distinct patter of histone acetylation observed for p300 and P/CAF. In fact, while p300/CBP acetylates the majority of the H3 lysines and all the H4 lysines acetylated in vivo, P/CAF acetylates only a subset of them (237) .
A possible level of discrimination between the HAT activity of p300 and P/CAF may reside in the observation that whilst MyoD itself is acetylated by both p300 (234, 217) and PCAF (234, 150) , only acetylation mediated by the latter causes an increase in DNA binding and modify MyoD conformation (235) . The functional relevance of MyoD acetylation is suggested by the observation that mutagenesis of the acetylated lysines reduces MyoD activity (234, 217) . Additional mechanisms -possibly involving the ability of MyoD to interact with or repulse a specific subset of cellular proteins in an acetylated-dependent manner-are likely to mediate the transcriptional effect of MyoD acetylation. A further support for a positive role MyoD acetylation derives from experiments in which recombinant MyoD was first in vitro acetylated using either p300 or P/CAF and then microinjected in mouse fibroblasts. Acetylated MyoD was more efficient in activating a muscle-specific reporter when compared to non-acetylated MyoD (217) . Considering that only a small fraction of recombinant MyoD can be acetylated in an in vitro acetylation reaction (V. Sartorelli and P.L. Puri, unpublished results), it is likely that the role of MyoD acetylation on transcription may have been underestimated. Both p300 and P/CAF acetylate overlapping lysines of MyoD and the artificial acetylation induced by either acetyltransferases in vitro (217) precludes to conclusively ascribe to either one or the other a role in acetylating MyoD in the cell. Additional experiments have suggested that the HAT of p300 may regulate MyoDdependent transcription. Frog oocytes microinjected with MyoD and p300 RNAs were subsequently re-microinjected with the p300 HAT-specific inhibitor Lys-CoA. After one hour the oocytes were microinjected with the frog MyoD promoter fused to 100 bp of its coding region and transcription evaluated using primer extension using a radiolabeled MyoD primer. The MyoD coactivation exerted by p300 was counteracted in a dose-dependent manner by Lys-CoA (135 (273, 98, 250, 92) . By directly interacting with p300 and P/CAF, both E1A and Twist inhibit their acetyltransferase activity (91,39) and indeed MyoD acetylation is blocked by either E1A or Twist (P.L.Puri, Y. Hamamori, and V. Sartorelli, unpublished results). Consistently, two studies have reported the identification of an endogenous E1A-like inhibitor of differentiation (the EID-1 protein), whose ability to prevent muscle-specific transcription correlates with the inhibition of p300 HAT activity (165, 148) . Whether EID-1 also blocks the acetyltransferase activity of P/CAF has not been investigated yet.
Additional studies will be required to clarify the very detailed mechanisms through which acetylation influence muscle differentiation. Nevertheless, it seems now clear that MyoD requires both SWI/SNF (55) and acetyltransferase activity (234, 217) to promote muscle -specific transcription and cell differentiation. Thus, it is possible that the ordered sequence of molecular events described in yeast for the HO gene (50) may well be taking place also for MyoD-dependent transcription in mammalian cells.
MEF2
The myocyte enhancer factors 2 MEF2 synergize with the myogenic bHLH factors in activating muscle transcription and differentiation (169) . Recently, such synergism has been shown to be mediated by the cell-cycle regulator and tumor suppressor pRb (187). MEF2-dependent transcription is augmented by p300 (233, 216) and this may rely on the fact that p300 interacts with MADS-box (233) of MEF2 (62). The myogenic bHLH also interact with the MADS-box of MEF2 (118,168) making it attractive to speculate that p300, myogenic bHLH and MEF2 may form a transcriptional complex. The apparently elevated concentration of p300 present in rabbit reticulocyte lysate (62) may in fact be responsible for the interaction between myogenin and MEF2 observed when reticulocyte lysate is employed to transcribe and translate these two proteins (168) . MEF2 is also in vitro acetylated by p300 (C.Poizat and L.Kedes, personal communication) but whether this modification is functionally relevant has not been investigated yet.
Using an analogy with the nuclear receptormediated transcription -where recruitment of p300-P/CAF has been suggested to involve the presence of the steroid receptor coactivator SRC-GRIP-1-(203), Chen et al. (45) have postulated that GRIP-1 may participate in regulating muscle differentiation. Indeed, these authors have found that GRIP-1 interacts with and coactivates MEF2C. Muscle cells expressing GRIP-1 antisense RNA do not activate muscle-specific transcription and fail to undergo differentiation. GRIP-1 also interacts directly with the myogenic bHLH myogenin but this interaction is not accompanied by functional transcriptional coactivation. Transcriptional coactivation exerted by GRIP-1 on MEF2C does not require DNA binding of the latter protein suggesting that, in muscle cells, the GRIP-1-MEF2C complex may be tethered on the DNA by another protein, possibly a myogenic bHLH. In view of the reported physical and genetic interaction of MEF2 with p300 and P/CAF (233, 160) , it will be of interest to biochemically purify complexes containing GRIP-1 to establish their protein composition in muscle cells.
The MEF2 factors control expression of the insulin-sensitive glucose transporter (GLUT4), the principal insulin-sensitive transporter in skeletal muscle, which has been implicated in the genesis of type 2 diabetes (295) . Recent studies suggest that GLUT4 expression in skeletal muscle is controlled by the concerted action of MEF2C and the cold-inducible coactivator PGC-1 (160) . Cultured muscle cells lack GLUT4 expression, which is promptly restored once the cultured cells are infected with an adenovirus expressing PGC-1. PGC-1 expression is accompanied by both GLUT4 expression and stimulation of both basal and insulin-stimulated glucose transport. Since the GLUT4 promoter is activated by MEF2 (261), the effects of PGC-1 on GLUT4 expression are likely due to its ability to directly interact with an activation domain of MEF2C and coactivates MEF2-dependent transcription. Removal of the PGC-1 region shown to interact with MEF2C should abrogate its ability to stimulate GLUT4 expression and insulin-stimulated glucose transport in cultured myotubes. At variance with other transcriptional coactivators, PGC-1 has no detectable intrinsic acetyltransferase activity (220) but recruits both p300 and SRC-1 acetylases (220) . Whether the enzymatic activities of p300/SRC-1 contribute to the effects of PGC-1 on GLUT4 gene expression remains to be determined.
Deacetylation
As predicted by the experiments conducted with acetyltransferases, their deacetylase counterparts impinge on muscle transcription and differentiation. Class II deacetylases have a N-terminal domain absent from class I deacetylases (81). It is this N-terminal region of HDAC 4 and 5 that serves as interface for interaction with MEF2 (163, 268) . HDAC 4 and 5 overexpression prevents skeletal myogenesis in culture and in vitro experiments indicate that the HDAC4/5-MEF2 complex may be present on MEF2-DNA binding sites, but this evidence is not supported by in vivo approaches (143) . Importantly, the repressive activity of HDAC 4 and 5 on muscle transcription was mapped to their deacetylase domain, even though residual repression was observed with deacetylase mutants. HDAC 4 and 5 do not interact with the myogenic bHLH but forced expression of MyoD restored activation of the MCK enhancer in the presence of exogenously transfected HDAC 5 (143) . Recently, the corepressor SMRT has been shown to be involved in maintaining both HDAC4 and 5 in the nucleus. Furthermore, in transient transfection experiments, SMRT synergizes with HDAC4-5 to mediate MEF2-dependent transcriptional inhibition (Wu et al., in press). MEF2 is a positive regulator of myogenesis. How is HDAC-mediated repression of MEF2 relieved? Upon differentiation of C2C12 muscle cells, HDAC 4 and 5 relocate from the nucleus to the cytoplasm (164, 157) , a phenomenon that is stimulated by the calcium/calmodulin-dependent protein kinase CaMK (157) . CaMK also impinges of HDAC-MEF2 interaction by phosphorylating HDAC 5 and dissociating it from MEF2 (142) . Therefore CaMK seems to favor muscle differentiation by two independent but functionally converging mechanisms: dissociation of HDACs from MEF2 (142) and cytoplasmic export of HDACs (157) .
Once shuttled to the cytoplasm, phosphorylated HDAC 4 and 5 are there retained via interaction with members of the 14-3-3 protein family (82, 269, 158) . MEF2 is also negatively regulated by the co-repressor MITR (248) . Isolated in a two-hybrid screening, MITR binds to both Xenopus XMEF2A and XMEF2D and represses MEF2-dependent transcription in injected oocytes. As suggested by protein-protein interaction studies, MITR is likely to mediate MEF2 repression by recruiting class I deacetylase HDAC1. In frog embryos, MITR is initially expressed within the mature somite and is later restricted to the myotomal muscle. Since both XMEF2A and D are expressed in differentiated skeletal muscle and in cardiac precursors, respectively, their interaction with MITR is likely to be developmentally regulated. Surprisingly, ectopic expression of MITR in the whole frog embryo shows no effect on myogenesis. Nevertheless, when two phosphorylated serine residues( Ser-218 and Ser-448) that regulate MITR interaction with 14-3-proteins are substituted with alanines, MITR becomes a repressor of myogenesis. These data suggest that stimuli favoring muscle differentiation may promote phosphorylation and subsequent cytoplasmic retention of MITR. Therefore, class II deacetylases and MITR undergo a similar cellular redistribution mediated by 14-3-3 proteins (290) Class I deactylase HDAC1 and 2 regulate muscle differentiation using a different mechanism from that described for HDAC 4 and 5. MyoD is transcriptionally inactive in undifferentiated myoblats and becomes competent once muscle cells initiate to differentiate. The inability of MyoD to promote transcription has been ascribed to the presence of Id1, an HLH protein devoid of the basic domain, that competes for binding to E-proteinsubiquitous bHLH proteins necessary for MyoD binding to DNA (17). This model has been substantiated by the in vivo findings that an E-box of the MCK enhancer is unoccupied in myoblasts and becomes "footprinted" in differentiated myotubes (173) . Nevertheless, several observations suggest an alternative scenario.
Overexpression of Id1 only retards differentiation without blocking it (113). Furthermore, the levels of several Id proteins (1-4) in myoblasts are much lower than those of E-proteins (274), rendering a direct titration effect unlikely. Additionally, genetic ablation of both Id 1 and 3 have revealed a role for these genes in neurogenesis and angiogenesis, but was without consequences on myogenesis (146) . Since Id 4 is not expressed in muscle (112), its hypothetical compensatory role can be excluded. Therefore, while Id can clearly counteract the activity of MyoD (17), additional mechanisms may operate to keep MyoD function in check (274) . Accordingly, MyoD has been found associated with class I HDAC1 in undifferentiated myoblasts (150) Biochemical experiments indicate that while HDAC1 is associated with MyoD in undifferentiated myoblasts, a pRb-HDAC1 complex -absent in myoblasts-is detected in differentiated myotubes (Puri et al., submitted) . Interaction between hypophosphorylated pRb and HDAC1 is functionally relevant since a single amino acid substitution introduced in pRb that abolish its binding to HDAC1 (46) also diminishes pRb-dependent coactivation of MyoD activity and activation of endogenous muscle gene expression (Puri et al., submitted) . The HDAC1-pRb interaction is also important for the establishment of the irreversible cell cycle arrest in terminally differentiated myotubes (46). Finally, the deacetylase inhibitor trichostatin A (TSA) anticipates muscle gene expression and favors differentiation when applied to undifferentiated myoblasts (Sartorelli et al., submitted) . Notably, embryos exposed during their fetal life to non-toxic doses of TSA display an increased number of somites expressing the myogenic bHLH Myf-5 (183).
NEUROGENESIS AND ENDOCRINE PANCREATIC DIFFERENTIATION
Tissue-specific bHLH proteins have been implicated in promoting neuronal and oligodendrocyte differentiation during development of the central nervous system (CNS). Genetic evidence has revealed the critical role of the bHLH proteins neurogenin (Ngn1 and Ngn2), Math1, Mash1 and NeuroD1/Beta2 during neuronal differentiation (85, 147, 16, 69, 166) whereas two other bHLH factors -oligo 1 and oligo 2 -are involved in oligodendrocyte differentiation (144, 293) . NeuroD1/Beta2 plays also an important role in development and differentiation of intestinal endocrine cells and endocrine pancreas (182) . The similarity in structure, function and regulation between these proteins and the muscle-specific bHLH regulatory factors suggests that acetyltransferases could also be involved in the regulation of both pancreatic cells and neuronal differentiation.
Indeed, several groups have reported both physical and functional interactions between p300/CBP and NeuroD1/Beta2. Mutoh et al. first showed that p300 could associate with NeuroD1/Beta2 to promote transcription of the secretin gene and to induce cell cycle arrest by enhancing p21 transcription in enteroendocrine cells (176) . This dual function of p300 in intestinal cells -induction of both tissue-specific gene expression and cell cycle arrestis reminiscent of the role of p300 during skeletal myogenesis and suggests that this coactivator may have a specific role in the induction of terminal differentiation. Further experiments have established the importance of p300 in mediating the activation of the insulin gene transcription in pancreatic β? cells. These studies have shown that p300 can potentiate NeuroD1/Beta2 dependent insulin transcription via an E-box site (225) . Notably, insulin expression is controlled by two critical cis-elements in the insulin promoter -the E-box binding site for NeuroD1/Beta2 and a PDX-1-binding element. Another study has suggested the importance of p300/CBP also in mediating PDX-1 dependent activation of insulin transcription (6). Thus, both NeuroD/Beta2 and PDX-1 can recruit p300/CBP to the regulatory region of the insulin gene. However, whether p300/CBP is preferentially recruited only by one or both these DNA binding proteins remains to be established. Since NeuroD1/Beta2 and PDX-1 are required for normal pancreas development (115, 197, 182) , p300 function is likely to be important during pancreatic differentiation. Interestingly, a p300 mutant in which amino acids 1680 to 1811 -a region next to the acetyltransferase domain -were deleted continued to coactivate NeuroD1/Beta2-dependent activation of insulin transcription (225) . However, whether the acetyltransferase activity of p300, or other p300-binding HAT proteins, is required for NeuroD1/Beta2-dependent transcription has not clearly addressed. The regions of NeuroD1/Beta2 that mediate the interaction with p300 were mapped within two evolutionary conserved sequences spanning the bHLH region and the C-terminal activation domain (241) . The same regions are necessary for activation of insulin transcription and ectopic neurogenesis upon injection of NeuroD1/Beta2 in Xenopus (241) . Remarkably, a mutation in the C-terminal domain of NeuroD1/Beta2, giving rise to a truncated peptide unable to associate with p300/CBP, has been identified in patients with type 2 diabetes (151), further underscoring the importance of p300-dependent coactivation in controlling insulin transcription. A defective function of p300 has also been reported in a rare autosomal dominant form of diabetes, which is characterized by an abnormal insulin secretion in response to glucose -the maturity-onset diabetes of the young (MODY). In this study, Soutoglou et al. show that two dominant-negative mutants of hepatocyte nuclear factor 1α (HNF-1α) detected in MODY3 patients can interact with CBP and P/CAF with a stronger affinity, as compared to the HNF-1 wild type. However, the CBP and P/CAF recruited by these HNF-1α mutants have deficient HAT activity (247) . Previous studies reported the ability of HNF-1 to recruit both CBP and P/CAF in one complex, with interactions of CBP to the N-terminal of HFN-1 increasing the association of P/CAF to the C terminal of HFN-1 (246). Furthermore, HNF4, which is also mutated in MODY1, requires both p300 and SRC-1/GRIP1 to activate target genes (271) .
Taken together, these observations establish a causative link between malfunctioning transcription and certain forms of diabetes. Specifically, they establish that in both type 2 diabetes and MODY1 disregulated transcription is consequent to defective acetyltransferase-dependent transcriptional coactivation.
A more complicated picture involving p300/CBP in the regulation of CNS development emerges from recent observations reporting on two distinct mechanisms controlling gene expression during cell fate specification of cortical progenitors (255) . Progenitor cells lining the ventricular cavities of the brain give rise to three cell types: neurons, astrocytes, and oligodendrocytes. In a series of elegant experiments, Sun et al. have provided evidence that Ngn1 associates with CBP to promote the expression of genes required for neurogenesis and, at the same time, to sequester the CBP-Smad1 complex away from STAT1 and STAT3, two critical inducers of astrocyte differentiation (255) . Thus, Ngn1/CBP complex formation mediates both induction of neurogenesis and inhibition of glial differentiation. Within cell-fate specification in the cerebral cortex , neurogenesis precedes gliogenesis. Therefore, the regulated recruitment of CBP into discrete protein complexes not only controls transcription of different set of genes but also dictates the temporal sequence of events leading to an ordered development of the CNS. The ability of proneural bHLH factors to inhibit gliogenesis is established also by genetic studies conducted in the mouse embryo (264, 186, 172) and confirmed in Xenopus embryo. Xenopus neurogenin-1 (XNGN-1) promotes the expression of genes required for neuronal differentiation by recruiting p300/CBP and P/CAF. Moreover, it was observed that the same complex (XNGN-1-p300/CBP-P/CAF) also activates the expression of genes that antagonize neuronal differentiation in neighbour cells -a process named lateral inhibition. While the HAT of p300/CBP and P/CAF seems to be important only during the activation of neuronal differentiation , it is dispensable for the regulation of genes involved in the lateral inhibitory pathways (129) . In agreement with these studies, Kato et al. have reported that inhibition of p300/CBP function leads to neural induction and primary neurogenesis in the entire embryo (117). p300/CBP and P/CAF are likely to be only part of a larger number of acetyltransferases involved in cerebral cortex development. In fact, Querkopf, a member of the MYST family of zinc finger histone acetyltransferases -which include MOZ, Ybf2/Sas3, Sas2, HBO-1 and Tip 60, reviewed in (252)-has also been implicated in the development of the cerebral cortex (262) . In this study, the authors show that Querkopf is strongly expressed in cells within the ventricular zone of the cortex and that mice homozygous for Querkopf mutations display defective cerebral cortex development (262) . Consistent with an essential role of MYST acetyltransferases in brain development, another MYST protein (the enoki mushroom, "enok") is required for the formation of the mushroom bodies -the centers for olfactory learning and memory in Drosophila brain. Interestingly, either genetic ablation of Enok or a point mutation within the zinc finger domain ,impairing its HAT activity, produces a block in neuroblast proliferation (240) . Given the recent observation of biochemical and genetic interactions between MYST family members and the replication factors mcm-2 and orc-1 (34) and the role of TIP 60 in DNA repair and apoptosis (102) , it is tempting to speculate that MYST HAT activity may be important in the process of DNA replication , proliferation and apoptosis of neural precursors during brain development. It is intriguing to note that also p300 null embryos show defect in neuralization and reduced DNA synthesis, suggesting that defective proliferation may be responsible for the neural phenotype in p300 nullizygous mice (288) . Finally, the involvement of HAT proteins in neuronal differentiation is underscored by the positive effects of deacetylase inhibitors on differentiation of established cultures of cells with neurogenic potentyial in vitro (106, 162) .
Coactivators, corepressors and neurodegenerative disorders
Huntington's disease (HD) and dentatorubral and pallidoluysian atrophy (DRPLA) are neurodegenerative disorders caused by an expansion of a polyglutamine tract in the huntingtin (htt) and atrophin-1 proteins, respectively (87, 86, 15). HD is clinically characterized by choreoathetotic movements and progressive dementia and is transmitted as an autosomal dominant disease (88, 211). Pathological features of HD include a distinctive atrophy of the caudate nucleus, the putamen and the globus pallidus (285). Histologically, neuronal intranuclear and cytoplasmic inclusions are observed in both transgenic mice expressing an amino-terminal fragment of htt (52) and HD patients (14). There is not presently form of treatment for HD. The neuronal inclusions contain a truncated form of htt and ubiquitin (57) . The acetyltransferase CBP has been shown to be present in nuclear inclusions of both transgenic mice and human HD and DRPLA postmortem brains (119, 251, 188) . Furthermore, co-localization and biochemical studies indicate that htt with expanded polyglutamine repeat sequesters CBP via interaction with a polyglutamine-rich region present on CBP (188) . The CBP-related p300 protein -which does not have a polyglutamine repeat-fails to interact with htt and it is not found in nuclear inclusions (188) . Furthermore, CBP mutants devoid of the polyglutamine repeat do not associate with htt. CBP is located in the nucleus. Upon interaction with htt, CBP is redistributed in the cytoplasm where it is found in htt aggregates (188) . Overexpression of htt with an expanded polyglutamine repeat, inhibits CBP-dependent transcriptional coactivation suggesting that CBP-mediated transcription may be defective in HD. Notably, CBP overexpresion can rescue htt-and atrophin-1-induced cellular toxicity (188) . Htt also interacts with the tumor suppressor p53 protein and the corepressor mSin3a (251) . CBP was found in postmortem brain of patients affected by the spinal bulbar muscular atrophy/Kennedy's disease-also caused by an expanded polyglutamine repeat (251) . The results of these studies are consistent with the possibility that expanded polyglutamine repeats of htt and atrophin-1 may disturb transcriptional regulation through interaction with coactivators, corepressors and transcription factors and that such disregulation may result in neuronal alterations and cell death. On this note, expression of the neuronal survival protein BDNF -which is coregulated by CBP via interaction with CREB-has been reported to be reduced in HD patients (66) . Furthermore, htt has been recently shown to up-regulate transcription of BDNF and to loose this property in HD patients (296).
CARDIAC GENE EXPRESSION AND MORPHOGENESIS.
A role for p300 in controlling cardiac gene expression and heart development emerges from three independent lines of evidence. As discussed in the previous paragraph, MEF2 activity is influenced by both acetyltransferases and deacetylases. MEF2C is expressed in heart precursor and mice homozygous for a MEF2C null mutation die before birth. No viable embryos are observed after E10.5 and the heart defects affect both atria and ventricles (140) . These defects include poor ventricular trabeculation and pericardial effusion, both signs of heart failure. The timing of interrupted development and phenotype of MEF2C null animals remarkably resemble those of p300 null animals (288) . At E10.5, 50% of p300 nullizygous are dead and show reduced heart trabeculation and severe pericardial effusion. A comparison of the transcriptional profiles of the MEF2 and p300 nullizygous animals cannot be drawn since the markers used in the two studies differ. In MEF2 nullizygous animals, transcripts for atrial natriuretic factor, cardiac α-actin and α-myosin heavy chain are severely downregulated whereas those for myosin light chain MLC2V and MLC2A are normal (140) . p300 null embryos have reduced levels of myosin heavy chain and α-actinin transcripts (288) . Given that p300 also regulates neurogenesis (see below), it is not surprising that p300 mutant embryos have also neural tube defects (288).
Further circumstantial evidence for a role of p300 in cardiac transcription derives from studies that employed the adenoviral E1A oncoprotein. Regions of E1A interacting with p300 (122) (95) and p107 (122) are necessary to mediate the inhibition exerted by E1A on cardiac gene expression. On the other hand, Bishopric et al. have reported that E1A-mediated inhibition of cardiac transcription is independent from its ability to interact with p300 (21). Nevertheless, in the same study p300 overexpresion could bypass the transcriptional repression exerted by E1A (21). The same authors have recently reported that MEF2D utilizes p300 to activate cardiacspecific transcription in primary isolated rat cardiomyocytes (244) .
Finally, a recent study implicates p300 in mediating the transcriptional effects of the cardiotoxic antineoplastic drug doxorubicin. Poizat et al. (216) have indicated that overexpression of p300 in primary neonatal cardiomyocytes augments MEF2-dependent transcription. This effect is due not solely to the ability that p300 has to coactivate MEF2 protein but possibly also to a p300-mediated increased transcription of the MEF2 gene itself. In this study, p300 is also shown to coactivate Nkx 2.5-mediated transcription. Doxorubicin represses skeletal and cardiac-specific transcription (133, 109) . Exposure of primary cardiomyocytes to doxorubicin causes repression of MEF2-dependent transcription and p300 overepression counteracts this effect (216) . Transcripts for the cardiac transcription factors MEF2C, dHAND, eHAND and NKX2.5-but not those of p300-are rapidly depleted upon doxorubicin treatments of primary cardiomyocytes. Interestingly, doxorubicin exposure induces proteasomemediated degradation of the p300 protein that may or may not be dependent on ubiquitination of p300 (216) . Degradation of p300 protein is observed also in C2C12 skeletal muscle cells and may be responsible-along with an increased transcription of the Id gene (133)-for the observed transcriptional repression exerted doxorubicin. Whether or not the effects that p300 seems to have on cardiac transcription and morphogenesis depends on its acetyltransferases activity remains to be determined in future studies.
HEMATOPOIESIS
In 1973, Axel, Cedar and Felsenfeld observed that the RNA polymerase derived from E.coli promoted transcription of globin genes derived from reticulocyte chromatin but not from either liver or brain chromatin (9). This observation was followed by a seminal paper by Weintraub and Groudine who reported that " globin genes are digested by deoxyribonuclease I in red blood cell nuclei but not in fibroblast nuclei" (279) and suggested that histones of the chromatin surrounding the globin genes in red blood cells are in a conformation that differs from that of the same genes in fibroblasts where globins are not produced. These studies established the technical and conceptual framework to investigate chromatin remodeling.
Chromatin remodeling
During erythroid maturation, expression of genes residing in the β-globin locus and encoding for embryonic, fetal and adult globins is temporally regulated to allow production of globin isoforms with different physicalchemical properties that better suit the distinct developmental stages of the organism. In particular, the transition from fetal to adult life is characterized by activation of adult β-globin genes δ and β and repression of the fetal γ-globin Gγ, Aγ and ψβ? genes (205) ? ?
The transcription factor Ikaros binds to a pyrimidine-rich sequence between the human fetal γ-globin and adult β-globin-like genes (194) . Deletion of this DNA region causes a delayed switch from fetal to adult globin expression in transgenic animals indicating that this region is involved in globin switch (193) . Ikaros is found associated with components of the SWI/SNF and NuRD remodeling complexes in extracts derived from mature erythroid cells (194) . While the SWI/SNF complex has an ATP-dependent remodeling acitivity -provided by either BRM or BRG1 subunits-(121) the NuRD complex contains both nucleosome remodeling and histone deacetylase activities provided by class I deacetylase HDAC1 and 2 and RbAp46/48. It is not clear whether Ikaros exists in two distinct complexes-one with nucleosome remodeling activity and the other with remodeling as well as deacetylase activity-(121). Furthermore, the functional relevance of the Ikaros-SWI/SNF-NuRD complex on globin isoform switching remains to be addressed.
The role of the transcription factor EKLF in fetal and adult hematopoiesis is more clearly defined. EKLF is a zinc-finger transcriptional activator required for fetal hematopoiesis (189) and ELKF nullizygous animals die because of β-thalassemia (209) . Interestingly, ELKF-/-animals display a delayed switch from fetal to adult globin expression (209) such as that observed in animals lacking the pyrimidine-rich sequence containing an Ikaros-binding site (193) . EKLF associates with the E-RC1 complex containing subunits of the SWI/SNF complex. In this case, chromatin remodeling and transcription driven from a chromatinized β-globin promoter requires both ELKFmore specifically its activation domain-and E-RC1 indicating a functional link between chromatin remodeling, transcription and complex formation (3). Recently, p300-mediated acetylation of EKLF has been reported to increase its affinity for the SWI/SNF complex (292) once again indicating an intimate relationship between chromatin remodeling and acetylation
Co-activation and acetylation
Numerous transcriptionl regulators participate in regulating erythroid differentiation and several of these proteins have been shown to interact and sense coactivation of p300/CBP. A comprehensive revision of the literature on the role of CBP/p300 in hematopoiesis is reported in (22). GATA-1 is a zinc finger-containing transcriptional activator required for erythroid (215, 214) and megakaryocytic proliferation and differentiation (242) . A point mutation abolishing binding of GATA-1 to the promoter region of the Duffy antigen/chemokine receptor gene (DARC), a blood group antigen, abolishes DARC expression in erythrocytes and it is responsible for its absence in Duffy-negative individuals (265) . GATA-1-dependent transcription is inhibited by the oncoprotein E1A (23) and is augmented by overexpressing p300/CBP (27) (23). While there is general agreement on the findings that p300/CBP promotes GATA-1 acetylation (23, 27), the molecular consequences on hematopoietic transcription have not been unequivocally determined and whilst a study indicates that acetylation enhances GATA-1 DNA binding (27) another has failed to detect such enhancement (23).
Besides recruiting the chromatin remodeling E-RC1 complex (3), EKLF interacts also with p300/CBP and P/CAF (291). Interestingly, both p300/CBP and P/CAF interact with EKLF but only p300/CBP, and not P/CAF, coactivates EKLF-dependent transcription. These findings correlate with the ability of p300/CBP and inability of P/CAF to acetylate EKLF both in vitro and vivo (291). Acetylated ELKF has an increased affinity towards the chromatin remodeling enzymes SWI/SNF and is a more effective transactivator when tested on chromatinized DNA templates (292)
Deacetylation
Sodium butyrate and trichostatin A, two deacetylase inhibitors, reactivate fetal γ-globin expression in adult erythroid cells (35, 210, 58, 108, 229). These observations suggest that deacetylation is a mechanism utilized during erythroid differentiation to silence gene expression. Isobutyramide, a derivative of butyric acid, can stimulate fetal hemoglobin production in patients with thalassemia intermedia (37). In vivo footprinting analysis conducted on erythroblasts isolated from patients with betaglobin disorders before and after butyrate therapy indicates the appearance of new "footprints' on the gamma-globin gene promoter of responsive patients. The footprinted region (BRE-G, for butyrate-response elements gamma) confers butyrate-inducibility in reporter gene assays (103) . Using as a model the human erythroleukemia K562 cells, McCaffrey et al. (156) showed that a CCAAT box and flanking sequences located in the gamma-globin promoter are critical for gene activation promoted by the histone deacetylase inhibitors butyrate, trapoxin, and trichostatin. Taken together, these studies suggest that the gene silencing that occurs on the fetal globin genes during adult hematopoiesis is an active process that can be reverted by the use of histone deacetylase inhibitors. Whereas the detailed molecular mechanisms leading to reactivation of fetal globin genes remain to be worked out, nonetheless, the treatment of hemoglobinopathies with histone deacetylase inhibitors offers an example of successful "chromatin" therapy.
LYMPHOCYTE DIFFERENTIATION
B and T lymphocytes and natural killer (NK) cells are likely to derive from a common lymphoid progenitor (126). Cues deriving from the extracellular milieu instruct uncommitted progenitors to choose between alternative fates (64) . Ikaros (see Hematopoiesis section) forms homo-and heterodimers with Aiolos (101,171) and is required for the development of a common lymphoid progenitor. In fact, animals with germline mutations in the DNA-binding domain of Ikaros lack B, T and NK cells whilst the erythroid and myeloid cells develop normally (24, 72, 49, 184, 185). Furthermore, a dominant mutation in the Ikaros gene is associated with the development of T and B leukemias and lymphomas in the mouse (282), T-cell acute lymphoblastic leukemia in children (253) and B-cell acute lymphoblastic leukemia in adults (179) .
Once the identity of the uncommitted lymphoid progenitor has been established, cells face the decision to take up either the B or T phenotype.
B cells
B-lymphocytes commitment is initiated by the two basic HLH EBF (139) and E2A gene products (294, 10, 11, 196) . B lymphocytes derived from mice with inactivated EBF or E2A genes are arrested at the earliest stage before rearrangement of the IgH gene (36). EBF and E2A genetically cooperate since compound heterozygous EBF+/-E2A+/-animals have a more severe B cell defect (195) . Furthermore, forced expression of E2A and EBF in hematopoietic precursors can synergistically activate transcription of several B-lymphoid-specific genes (243) (120). The E2A and EBF gene products activate expression of the downstream target Pax5 (195) , which is required for B cell commitment and development beyond the early pro-B cell stage. The normal expression of E2A in Pax5-/-pro-B cells indicate that the bHLH proteins are hierarchically upstream of Pax5 (191) .
As elegantly shown by Nutt et al. (192) , the initial activation of Pax-5 expression is stochastic, reversible, monoallelic and independent of the parental origin. Pro-B cells derived from Pax5-/-animals exhibit fascinating properties. When cultured in vitro, they have the ability to redirect their fate according to extracellular stimuli. In the presence of macrophage-colony-stimulating factor (M-CSF), they differentiate into macrophages, when exposed to granulocyte-CSF they become granulocytes, they differentiate into NK when treated with IL-2, into dendritic cells when treated with granulocyte-macrophage CSF and osteoclasts when challenged with TRANCE (190) . Some of the properties of Pax5-/-cells are observed also in the animal. For instance, when injected into RAG2-deficient mice, Pax5-/-pro-B cells acquire the T cell phenotype (230) and become osteoclasts when introduced in osteoclasts-deficient c-fos-/-mice (80).
The behavior of Pax5-/-cells indicates that while Pax-positive pro-B cells are destined to the B-lymphoid lineage, their Pax5-/-counterparts are far from being committed and retain multilineage capabilities. It also suggests that Pax5 is required to repress genes necessary for later stages of B-cell development. Examples of genes repressed by Pax5 are those encoding for the M-CSF receptor, myeloperoxidase, perforin, and GATA-1 (190) .
T cells
The molecular understanding of T cell commitment and differentiation is less advanced if compared to what it is known for B cells (207) . Beside its role in establishing lineage commitment (see above), Ikaros is also involved in controlling critical stages of thymocyte differentiation (281, 8 ). An additional regulator of thymocyte differentiation is the zinc-finger-containing transcription factor GATA-3. GATA-3 is required for development of T-cells in vitro (132) . Since GATA-3 -/-nullizygous animals are embryonic lethal (208) , embryonic stem (ES) cells derived from GATA-3 -/-animals were employed to populate mice with a RAG2-/-genotype. The GATA-3-/-embryonic stem cells were unable to contribute to CD4-/CD8-double-negative cell indicating that T cell development is blocked at the earliest stage (263) . The transmembrane protein Notch1 has been implicated in establishing the specification of the T cell fate (206) . Analogously to GATA-3 nullizygous animals (208), Notch1-/-embryos die early (256). Using a conditional gene inactivation protocol, Radtke et al. have shown that T cells development in Notch-/-animals is arrested at the most immature stage whereas differentiation along the B cell and other hematopoietic lineages is preserved (226) . Interestingly, immature B cells were observed in the thymus (226) . A complementary approach has utilized the intracellular domain (constitutively active form) of Notch1 delivered by infecting the bone marrow of mice with a Notch-expressing retrovirus (219) . In this case, T cell development ectopically occurred in the bone marrow and was thymus-independent. Furthermore, B cell development was impaired (219) . The results of these experiments suggest that there is a cross-talk between B and T cell development whose molecular basis may reside in the ability of Notch to interfere with the transcriptional activity of the bHLH protein E47 (219, 204) . According to this scenario, Notch signaling would prevent maturation of B lymphocytes from the uncommitted progenitor via E2A blockade and would-by default-promote T lymphocytes development through a secondary fate instructive commitment in the thymus. Finally, recent evidence indicates that Notch may protect developing T cells from programmed cell death (56, 111).
Co-activation and acetylation
GATA-3-dependent transcription is augment by p300 and p300 can acetylate in vitro GATA-3. Importantly, GATA-3 is acetylated in T cells (286) . Substituting the acetylated lysines with arginines decreases GATA-3 acetylation and impairs its ability to transactivate. To address the role of GATA-3 acetylation in T cell function, Yamagata et al. (286) have expressed a non-acetylatable (KRR-GATA3) form in the T-cells of transgenic mice using the T-cellspecific Lck distal promoter. The spleen derived from KRRGATA3 mice was enlarged with an increased T/B cell ratio. An increased T cell population was also evident in the peripheral blood whereas the peripheral lymphnodes and the Peyer's patches displayed a decreased presence of T cells. The cellular basis of the abnormal ratio of T/B cells in different organs seems to reside in both a defective homing and increased survival of the T cells. To date, this is the study (286) that more directly assesses the role of acetylation in controlling the function of transcription factors in the animal. Mutations of two lysines to arginines (KKK>KRR) as those present in KRR-GATA3 are not expected to induce significant conformational changes in GATA3. Nevertheless, this possibility should be taken into account when interpreting the data obtained with the KRR-GATA3 mice.
The E2A gene products E12 and E47 interact with and are coactivated by p300 (62, 204). As with MyoD, the E12 interaction sites may be multiple since both the HLH (62) and the activation domains AD1 and AD2 of E12 have been reported to interact with p300 (225) . The AD1 and AD2 activation domains are conserved in the other members of the bHLH family, E2-2 and HEB (153). Within the AD1, the LDFS motif is conserved in the yeast bHLH transcription factor Rtg3p. A series of genetic and biochemical experiments indicate that the LDFS motif of both the E2A and Rtg3p mediate transcriptional activation and is required to recruit purified yeast SAGA complex, containing an acetyltransferase activity (152). The ability of the mammalian equivalent of the yeast SAGA complex, P/CAF and hGCN5 to interact with E2A was not investigated in this study. Nevertheless, the biochemically indistinguishible properties of the SAGA (77) and P/CAFhGCN5 (198) complexes suggest that the transactivation domain AD1 may interact with P/CAF/hGCN5. The requirement for the HAT activity of SAGA to sustain E2A transcriptional activation has not been addressed yet.
Gene silencing and deacetylases
Depending on the experimental conditions, Ikaros can either promote or inhibit transcription. In proliferating lymphocytes, a significant fraction of Ikaros is found at centromeric DNA in close association with heterochromatincontaining foci (31), suggesting that Ikaros may be involved in gene silencing. Ikaros, and Aiolos co-localize with the DNA-dependent ATPase Mi-2 and the deacetylase HDAC-1 at discrete DNA foci located at heterochromatin regions (121, 125). The Ikaros-associated proteins have the ability to remodel chromatin in vitro and deacetylate histones (121). Ikaros also interacts with the co-repressor C-terminal binding protein (CtBP) and mutations in Ikaros preventing CtBP binding reduce its ability to repress transcription (124). CtBP represses transcription in a histone deacetylase-independent manner indicating that Ikaros utilizes both dependent-and independent-deacetylase strategies to silence transcription. In agreement with its transcriptional stimulatory properties, Ikaros was also found associated with the chromatin remodeling machine SWI/SNF (194) . Therefore, Ikaros is present in two separable protein complexes, one containing Mi-2 and HDAC-1 (121) and the other SWI/SNF (194) . Interestingly, the composition and location of the Ikaros-complexes is dynamic and subject to modification according to the different phases of the cell cycle. These biochemical findings support the notion that Ikaros (and Aiolos) may behave as either transcriptional activators or repressors, depending on the cellular circumstances.
Recently, the transcriptional repression properties of Pax5 have been associated with its ability to recruit corepressors of the Groucho/TLE protein family (59) .
Upon interaction with its cellular receptors Jagged and Delta, the transmembrane receptor Notch (4) (5) is processed and its intracellular (IC Notch) domain is translocated to the nucleus (239) The genes regulated by Notch in T cells have not been identified yet. Nonetheless, a clue on the potential targets has come from the observation that expression of IC Notch protects both T cell lines and thymocytes from apoptosis induced by glucocorticoids (56) . During negative selection, thymocytes undergo apoptosis mediated-at least in part-by the nuclear hormone receptor Nur77 (141, 284) . Recent experiments indicate that Notch1 causes repression of Nur77 activity suggesting a molecular explanation of the protective role of Notch in T cell death (111).
Acetyltransferases and Disregulated Hematopoiesis
Patients affected by the Rubinstein Taybi syndrome (RTS) bear mutations in one CBP allele (see below) and have an increased incidence of cancers (161). Furthermore, biallelic mutations of the p300 gene have been described in some patients with gastrointestinal cancers (174) . Therefore, CBP/p300 (74) and the associate factor P/CAF (238) have been proposed to behave as tumor suppressor genes. This hypothesis seems to be substantiated -at least for CBP-by a genetic analysis conducted in animals with a monoallelic inactivation of the CBP gene (131) . These animals recapitulate some features of the RTS including growth retardation and craniofacial abnormalities. Unexpectedly, CBP heterozygous animals display also multiple abnormalities of the hematopietic system including splenomegaly, reduced bone marrow cellularity and deficiencies in pre-B cell and myeloid colony-forming progenitor cells (131) . On the other hand, p300 heterozygous animals do not reveal any hematopoietic abnormality. As the CBP heterozygous animals age, histiocytic sarcomas, myelogenous and lymphocytic leukamias develop. These malignancies can be transmitted to sublethally irradiated recipients transplanted with either bone marrow or spleen cells derived from tumor-affected donors (131) . Consistent with a tumor-suppressor activity of CBP, tumors derived from CBP hemyzygous animals reveal loss of the second CBP allele (131) . Several questions can now be addressed including the specific role of CBP in hematopoiesis and the target genes of CBP coactivation . To address the role of the acetyltrasnferase activity of CBP in the genesis of these malignancies , it will be of interest to reconstitute the CBP hemyzygous animals with a HAT-deficient allele of CBP.
The MYST acetyltransferase MOZ and the mixed-lineage leukemia (MLL) are often translocated in acute leukemias or myelodysplasia secondary to therapy with drugs that target DNA topo isomerase II, respectively, to either the p300 or CBP locus giving rise to fusion proteins composed of either MOZ-CBP (26), MOZ-p300 (123) or MLL-CBP (245) . Fusion of MLL occurs with the bromodomain and the HAT region of CBP. Bone marrow trasnplantation of cells trasnduced with the MLL-CBP protein induces myeloid leukemia in recipient animals (136) . The bromodomain and the HAT region of CBP fused to the amino region of MLL are sufficient to induce leukemia (136) suggesting an active role of the acetyltransferase activity of CBP in leukemogenesis. The MOZ region translocated to CBP retains the HAT domain (138) but whether this has any role in neoplastic transformation has not been addressed.
MELANOCYTES AND SKELETAL DEVELOPMENT
As indicated by genetic inactivation studies, the bHLHZip transcription factor Microphtalmia (Mi) regulates melanocyte differentiation and survival (100) . While Mi expression is up-regulated in response to exposure to melanocyte stimulating hormone, Mi activity is induced upon stimulation of the c-Kit signaling pathway. Concomitantly, the c-Kit pathway activates the MAPK system, which in turn phosphorylates Mi (20, 99). Phosphorylated Mi recruits p300/CBP, which enhances the transcriptional activity of Mi (218) . The p300/CBP binding region of region of Mi was mapped at the N-terminal activation domain and the synergistic activation of transcription could be inhibited by E1A (236) . Genetic studies have also implicated CBP function in the development of the skeletal system. Abnormal skeletal patterning was observed by Tanaka et al. in embryos lacking one CBP allele (258) . This phenotype is reminiscent of the Rubinstein Taybi syndrome (RTS), an autosomal dominant disease associated with mutation of CBP gene (213) . Another study has subsequently showed that heterozygous CBP-deficient mice with a truncated CBP protein (residues 1-1084) exhibit a typical RTS phenotype, indicating that CBP mutations may produce a dominant negative molecule (200) . Finally, Murata et al. have identified in human RTS patients mutations which may impair the HAT activity of CBP, implicating that acetylation may play an important role in skeletal development and related diseases (175) .
The involvement of p300/CBP and other acetyltransferases in differentiation of additional cell lineages as well as in the development of other animal models (e.g. Drosophila and Xenopus) are illustrated in other excellent reviews (76).
CONCLUDING REMARKS
The molecular foundations of chromatin remodeling and acetylation have begun to be clarified. Perhaps one of the most intriguing observations relates to the differential roles of even closely related acetyltransferases and deacetylases in controlling distinct cellular processes (223, 291) . Specific inhibitors that interfere with the acetyltransferase activity of either p300/CBP or PCAF/GCN5 are already available (135) and may be used to selectively interfere with cellular processes such as apoptosis and differentiation. Clearly, these compounds have the potential to be employed as therapeutical tools. Deacetylase inhibitors are already used in clinical trials (see Hematopoiesis) (272, 79) Acetylation seems to act in concert with other post-translational modifications including histone phosphorylation (for a review see (47) and methylation (1, 40, 180, 13, 270) for a review see (227) suggesting that combinatorial histone (and perhaps transcription factors) modifications may serve as a"code" to either attract or repulse transcriptional complexes. Elucidation of the temporal and spatial modifications will allow to interfere with specific cellular functions.
Only five years have passed since the initial isolation and characterizations of nuclear acetyltransferases (33) and deacetylases (260) 
